Who is sponsoring NCT02607592?

NCT02607592 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT02607592?

Interventions in NCT02607592: cisplatin and pemetrexed, nedaplatin+pemetrexed.

What condition does NCT02607592 study?

NCT02607592 studies Carcinoma，Non-Small-Cell Lung.

Is NCT02607592 still recruiting?

NCT02607592 is currently status unknown. Last updated 8 February 2022.

Last reviewed 2022-02-08 · How we verify

NCT02607592: NACA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nedaplatin or Cisplatin Combined With Pemetrexed in the First Line Treatment of Advanced Adenocarcinoma：A Prospective Multi-center Phase III Randomized Controlled Trial

Status unknown Phase 3 Last updated 8 February 2022

What this trial tests

Phase 3 trial testing cisplatin and pemetrexed in Carcinoma，Non-Small-Cell Lung in 293 participants. Status unknown.

Timeline

1 August 2015

Primary endpoint
1 June 2022

1 December 2022

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	293
Start date	1 August 2015
Primary completion	1 June 2022
Estimated completion	1 December 2022
Sites	1 location across China

Drugs / interventions tested

cisplatin and pemetrexed — full drug profile →
nedaplatin+pemetrexed — full drug profile →

Conditions studied

Carcinoma，Non-Small-Cell Lung — all drugs for Carcinoma，Non-Small-Cell Lung →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Carcinoma，Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

progression free-survival（PFS）
Time frame: 12months
Progression-free survival is defined as the time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first

Sponsor's own description

The purpose of this study is to investigate the PFS, ORR, OS and overall toxicity value（OTV）on advanced adenocarcinoma treated with nedaplatin or cisplatin combined with pemetrexed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02607592 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 8 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02607592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing